The stock of Trevi Therapeutics Inc (NASDAQ:TRVI) last traded at $2.50, down -1.57% from the previous session.
TRVI stock price is now -16.25% away from the 50-day moving average and 17.48% away from the 200-day moving average. The market capitalization of the company currently stands at $176.10M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $6, B. Riley Securities recently initiated with Buy rating for Trevi Therapeutics Inc (NASDAQ: TRVI). On November 22, 2022, SVB Leerink recently initiated its ‘Outperform’ rating on the stock quoting a target price of $6, while ‘Stifel’ rates the stock as ‘Buy’
In other news, Delfini Lisa, Chief Financial Officer sold 4,350 shares of the company’s stock on May 22 ’24. The stock was sold for $11,485 at an average price of $2.64. Upon completion of the transaction, the Chief Financial Officer now directly owns 53,279 shares in the company, valued at $0.13 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 20 ’24, President & CEO GOOD JENNIFER L sold 25,037 shares of the business’s stock. A total of $71,576 was realized by selling the stock at an average price of $2.86. This leaves the insider owning 213,313 shares of the company worth $0.53 million. A total of 35.39% of the company’s stock is owned by insiders.
During the past 12 months, Trevi Therapeutics Inc has had a low of $0.97 and a high of $4.00. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 14.55, and a quick ratio of 14.55. The fifty day moving average price for TRVI is $2.9724 and a two-hundred day moving average price translates $2.1289 for the stock.
The latest earnings results from Trevi Therapeutics Inc (NASDAQ: TRVI) was released for 2024-03-31. According to the Biotechnology Company, earnings per share came in at -0.07, beating analysts’ expectations of -0.08 by 0.01. This compares to -$0.06 EPS in the same period last year. The company reported revenue of $11.91 million for the quarter, compared to $7.56 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 57.42 percent.
